Picture of Genincode logo

GENI Genincode News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

REG - GENinCode PLC - CARDIO inCode-Score presentation

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240828:nRSb8675Ba&default-theme=true

RNS Number : 8675B  GENinCode PLC  28 August 2024

GENinCode Plc

("GENinCode" or the "Company")

 

CARDIO inCode-Score® presentation on polygenic risk of Coronary Heart Disease

at 2024 European Society of Cardiology (ESC) Annual Congress, London

 

Oxford, UK. GENinCode Plc (AIM: GENI), the polygenics company focused on the
prevention of cardiovascular disease and ovarian cancer, announces the
presentation by Kaiser Permanente on the interplay between family history and
polygenic risk on the incidence of coronary heart disease ("CHD") which will
take place at the 2024 Annual Congress of the European Society of Cardiology
("ESC") in London from 30 August to 2 September 2024.

 

Following the March 2024 milestone publication in the American Journal of
Preventive Cardiology(1), this latest study shows CARDIO inCode-Score® PRS
and family history in first degree relatives independently contribute to the
risk of incident CHD, with a 42% increase in risk in the presence of a
positive family history and a 64% increase where the patient has a high
polygenic risk score ("PRS"). Importantly, the study showed the joint effect
of positive family history and a high polygenic risk increased the hazard or
incidence of CHD by 2.3 times. Thus, relying solely on self reported (patient)
family history is insufficient to fully characterise the genetic contribution
to CHD and PRS is recommended.

 

The Kaiser Permanente Division of Research study investigated more than 63,000
adult individuals with no history of CHD who are part of the Kaiser Permanente
Northern California Genetic Epidemiology Resource in Adult Health and Aging
("GERA") multi-ethnic cohort. The GERA cohort followed the membership over an
average of 14 years, using CARDIO inCode-Score® to assess the polygenic risk
of CHD and future incidence of risk of CHD.

 

Individuals with a high polygenic risk of CHD should be prioritised for
lifestyle advice and where appropriate therapeutic intervention as those at
the highest polygenic risk will benefit most from earlier and/or more
intensified treatment, especially where they have family history. Previous
data on CARDIO inCode-Score® presented at last year's ESC showed that where
individuals have a high polygenic risk, a favourable lifestyle is associated
with a 52% lower rate of CHD compared with an unfavourable lifestyle. The
latest study continues to underline the need for 'polygenic risk score'
lifetime risk assessment in conjunction with traditional clinical risk
assessment (including family history) to optimise preventive care strategies
and lower the future risk of CHD.

 

Polygenic risk assessment can be undertaken in younger people, before
conventional clinical risk factors (such as high blood pressure, diabetes,
etc.) have developed, and can be combined with conventional risk scoring in
older people. In this way clinicians can more accurately identify those most
likely to benefit from lifestyle and therapeutic intervention (precision
medicine).

 

In the UK around 7.6 million people live with heart and circulatory disease,
which causes 25% of all UK deaths annually. Cardiovascular Disease ("CVD") can
be reduced by identifying and treating individuals at risk, with the NHS 10
Year Plan (2019) setting out to address CVD prevention.

 

Matthew Walls, CEO of GENinCode  said: "This latest ESC presentation on
CARDIO inCode-Score® continues to strengthen the clinical utility and
importance of polygenic risk assessment to identify individuals in the
population at high genetic risk enabling targeted treatment to prevent
coronary heart disease."

 

(1.) https://www.sciencedirect.com/science/article/pii/S2666667724000291
(https://www.sciencedirect.com/science/article/pii/S2666667724000291)

 

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 

 GENinCode Plc                      www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO

 Cavendish Capital Markets Limited  Tel: +44 (0)20 7397 8900
 Giles Balleny /Dan Hodkinson (Corporate Finance)
 Nigel Birks/ Harriet Ward (Corporate Broking)
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                                  Tel: 020 7933 8780 or genincode@walbrookpr.com

 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventive care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict and
prevent cardiovascular disease.

 

About CARDIO inCode-Score® (CIC-SCORE)

CIC-SCORE is a first in class in-vitro diagnostic test used to assess an
individuals genetic risk of CHD. The test is based on published clinical
evidence amassed over 15 years which, combined with traditional clinical risk
factors, provides a comprehensive risk assessment of CHD for use in primary
preventive care. GENinCode labs process patient DNA (extracted from saliva or
blood samples) and deliver the CARDIO inCode-Score® test results to
physicians via an online cloud based algorithmic (AI) reporting system
('SITAB').

 

CIC-SCORE also addresses the well-recognised need for improvement in the
cardiovascular disease (CVD) standard of care across ethnicities where
individuals from certain racial and ethnic groups face higher risks of CVD.
The CIC-SCORE test provides an improved estimation of an individual's risk of
heart attack over their lifetime, particularly within a 10-year period post
testing when combined with traditional clinical risk assessment. The CIC-SCORE
polygenic risk score enables a major improvement in patient CVD risk
assessment, preventive care and personalised treatment to reduce the incidence
of major adverse cardiovascular events (MACE), such as heart attack.

 

About Cardiovascular Disease (CVD):

Heart and circulatory disease also known as cardiovascular disease (CVD) is
the leading cause of death globally, taking an estimated 17.9 million lives
each year, with Coronary Heart Disease (CHD) representing the leading
cause of death for men, women, and people of most racial and ethnic groups
in the United States. CVD is a group of disorders of the heart and blood
vessels that include coronary heart disease, cerebrovascular disease,
rheumatic heart disease and other conditions. More than four out of five CVD
deaths are due to heart attacks and strokes, and one third of these deaths
occur prematurely in people under 70 years of age. By 2030 the global cost
of CVD is set to rise from approximately US$863 billion in 2010 to US$1,044
billion and is both a major health issue and global economic burden.

 

Cardiovascular disease, causes a quarter of all deaths in the UK and is the
largest cause of premature mortality in deprived areas and is the single
biggest area where the NHS can save lives over the next 10 years. CVD is
largely preventable, through lifestyle changes and a combination of public
health and action on smoking and tobacco addiction, obesity, tackling alcohol
misuse and food reformulation. Lifestyle "risks factors" are measured in
primary care facilities and indicate an increased risk of heart attack,
stroke, heart failure and other complications.

 

Identifying those at highest risk of CVDs and ensuring they receive
appropriate treatment can prevent premature deaths.

 

The current standard of care for assessing cardiovascular risk is primarily
based on traditional clinical risk factors such as age, sex, smoking, body
mass, blood pressure and cholesterol levels from which individuals are
categorised as being at low, moderate or high risk of a CVD event. This
categorisation is imperfect as CVD events frequently occur in those thought to
be at low or moderate risk. The size of the populations at low or moderate
risk are much larger than those at high or very high risk so whilst the
relative risk of a CVD event may be small, the absolute number of CVD events
in low and moderate risk populations is much greater than the number of events
in higher risk categories.  It is clear that the earlier in life preventive
measures can be put in place the lower the future risk.

 

Clinicians have for many years recognised the importance of prior CVD events
within the families of their patients because genetic factors contribute to
the development of atherosclerosis and a patient's family history has become a
surrogate for their inherited genetic risk. In recent years, with the advances
of genomics, it has proved possible to add genetic profiling to conventional
CVD risk factors, the combination of the two (genetics and conventional
clinical risk factors) enhancing the predictive capability of patient risk
thereby resulting in a personalised and preventive approach to CVD.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZDLFLZVLXBBZ

Recent news on Genincode

See all news